Skip to main content
Log in

Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18 FDG PET: report of three cases

  • Case Report
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Idiopathic retroperitoneal fibrosis is an uncommon disease characterized by periaortic inflammation with gradual fibrosis and distortion of retroperitoneal structures such as the ureter. Several earlier case reports have documented hypermetabolic retroperitoneal activity on fluorodeoxyglucose positron emission tomography (FDG PET) in patients with active disease, and a decrease in the activity following immunosuppressive therapy. We report FDG PET positive findings in three patients presenting with active retroperitoneal fibrosis. In two cases, enhancing periaortic soft tissue seen on computed tomography (CT) markedly diminished following immunosuppressive therapy. In one patient, repeat FDG PET was performed following immunosuppressive therapy, with complete resolution of the retroperitoneal FDG avidity. We suggest that FDG PET may play a useful adjunct to anatomic imaging and serum inflammatory markers in assessing the severity of inflammation in retroperitoneal fibrosis, and in assessing the likelihood of response to immunosuppressive therapy. FDG PET may also be used in follow-up to assess therapeutic response if CT findings are unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hughes D, Buckley PJ. Idiopathic retroperitoneal fibrosis is a macrophage-rich process: implications for its pathogenesis and treatment. Am J Surg Pathol 1993;17:482–490.

    Article  PubMed  CAS  Google Scholar 

  2. Vaglio A, Greco P, Corradi D, Palmisano A, Martorana D, Ronda N, et al. Autoimmune aspects of chronic periaortitis. Autoimmun Rev 2006;5:458–464.

    Article  PubMed  Google Scholar 

  3. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsarinne K, Saha H, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004;363:1422–1426.

    Article  PubMed  CAS  Google Scholar 

  4. Aziz F, Conjeevaram S, Phan T. Retroperitoneal fibrosis: a rare cause of both ureteral and small bowel obstruction. World J Gastroenterol 2006;12:7061–7063.

    PubMed  Google Scholar 

  5. Dejaco C, Ferenci P, Schober E, Kaserer K, Fugger R, Novacek G, et al. Stenosis of the common bile duct due to Ormond’s disease: case report and review of the literature. J Hepatol 1999;31:156–159.

    Article  PubMed  CAS  Google Scholar 

  6. Vivas I, Nicolas AI, Velazquez P, Elduayen B, Fernandez-Villa T, Martinez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestations. Br J Radiol 2000;73:214–222.

    PubMed  CAS  Google Scholar 

  7. Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005;23:231–234.

    PubMed  CAS  Google Scholar 

  8. Takahashi M, Momose T, Kameyama M, Ohtomo K. Abnormal accumulation of F18 fluorodeoxyglucose in the aortic wall related to inflammatory changes: three case reports. Ann Nucl Med 2006;20:361–364.

    Article  PubMed  Google Scholar 

  9. Kubota K, Yamada K, Yoshioka S, Yamada S, Ito M, Ido T. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992;17:361–363.

    Article  PubMed  CAS  Google Scholar 

  10. Cheung WS, Meller J, Vosshennrich R, Middel P, Becker W. Ormond’s disease: appearance in [F-18] FDG PET imaging. Nucl Med 2002;41:N44–N47.

    CAS  Google Scholar 

  11. Agrawal A, Nair N, Baghel N. F-18 FDG PET in Ormond disease in a patient with renal cell carcinoma. Clin Nucl Med 2007;32:320–322.

    Article  PubMed  Google Scholar 

  12. Nakajo M, Jinnouchi S, Noguchi M, Uozumi K, Tanabe H, Tateno R, et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med 2007;32:282–285.

    Article  PubMed  Google Scholar 

  13. Tanabe T, Tsushima K, Yasuo M, Urushihata K, Hanaoka M, Koizumi T, et al. IgG4-associated multifocal systemic fibrosis complicating sclerosing sialadenitis, hypophysitis, and retroperitoneal fibrosis, but lacking pancreatic involvement. Int Med 2006;45:1243–1247.

    Article  Google Scholar 

  14. Drieskens O, Blockmans D, Van den Bruel A, Mortelmans L. Riedel’s thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomographic findings. Clin Nucl Med 2002;27:413–415.

    Article  PubMed  Google Scholar 

  15. Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of idiopathic retroperitoneal fibrosis. Arthritis Care Res 2005;53:122–125.

    Article  Google Scholar 

  16. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005;35:186–196.

    Article  PubMed  Google Scholar 

  17. Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann, K, et al. Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003;30:730–736.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Phillip M. Young.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, P.M., Peterson, J.J. & Calamia, K.T. Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18 FDG PET: report of three cases. Ann Nucl Med 22, 87–92 (2008). https://doi.org/10.1007/s12149-007-0077-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-007-0077-0

Keywords

Navigation